![](https://impilo.se/wp-content/uploads/2024/03/impilo-340x260.webp)
Impilo AB, the Nordic investment company focused on healthcare investments, has secured new commitments from new and existing investors of SEK 6bn (EUR 590m) and significantly exceeding its target amount. The capital raised enables new platform investments and follow-on investments in existing portfolio companies. In combination with the value of the current portfolio, Impilo’s total assets under management now exceed SEK 10bn (EUR 980m).
Read moreNews
![](https://impilo.se/wp-content/uploads/2024/09/MiniGo_600x337_130324-315x300.png)
Impilo acquires Qufora in partnership with existing shareholders
Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.
![](https://impilo.se/wp-content/uploads/2024/04/ana-francisconi-1436548-unsplash-315x500.jpg)
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
![](https://impilo.se/wp-content/uploads/2024/02/cris-trung-3wK7RLRAAkA-unsplash_aviapharma_landingpage-qj7uiwo7cyjal8ag8kydvsn338wmo96z2gi19upjgw.jpeg-315x300.webp)
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.